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mRNA.11 As opposed to miRNAs, long noncoding RNAs (lncRNAs) 
are much less studied. LncRNAs are further categorized as intergenic, 
intronic, exonic, antisense, or overlapping based on the genomic 
location relative to a protein-coding gene, as shown in Figure 1.12,13 
The significance of lncRNAs in cancers is rapidly gaining attention 
because of recent studies discovering tens of thousands of novel, 
unannotated lncRNAs.14,15
In the past, a major hurdle in lncRNA research was the inability of 
conventionally utilized microarrays to detect lncRNA expression due to 
the lack of lncRNA-directed probes, hence limiting our understanding 
of the role of lncRNAs in prostate cancer. However, recent advances 
in transcriptome sequencing  (RNASeq) technologies have allowed 
the study of gene expression in an unbiased manner, resulting in the 
discovery of thousands of novel RNA species including lncRNAs. 
One initial study identified 121 lncRNAs, termed as PCATs (prostate 
cancer-associated noncoding transcripts), using ab initio computational 
approaches on RNASeq data from 102 prostate cancer tissue 
samples.15 The expression pattern of these 121 lncRNAs distinguished 
benign, localized, and metastatic prostate samples.15 More recently, 
a significant effort has been made both by our group and others to 
discover a landscape of lncRNAs in the human transcriptome using 
bioinformatics-based approaches. This study employed RNAseq data 
from 25 independent studies comprising over 7000 RNAseq libraries 
from tumors, normal tissues, and cell lines.14 Over 50 000 lncRNAs were 
identified, of which 79% were novel or unannotated, thus quadrupling 
the number of known lncRNAs.14 Importantly, about 8000 lncRNAs 
INTRODUCTION
In the past decade, numerous studies have helped unravel the 
molecular and biological processes that contribute to prostate 
cancer (PCa) development. With the advent of whole genome- and 
exome-sequencing, scientists have deciphered various genomic 
alterations contributing to PCa pathogenesis.1,2 The loss of one copy 
of the tumor suppressor PTEN has been found in approximately 60% 
of men with PCa.3 Mutations in p53, BRCA1 and BRCA2, and loss of 
RB have also been reported in smaller proportions of PCa cases.4–6 
Moreover, chromosomal rearrangements such as TMPRSS2‑ETS 
gene family fusions have been found frequently in Caucasian PCa 
cohorts.7 In addition to mutations and chromosomal translocations, 
epigenetic alterations have also been associated with PCa. For instance, 
hypermethylation at the promoter regions of PTEN, RB, and CDH1 is 
associated with advanced PCa.8
However, while the majority of these previous studies has focused 
on protein-coding genes, recent studies have suggested that only 2% 
of the genome is comprised of protein-coding genes.9 Strikingly, the 
vast majority of the genome  (around 70%) is actively transcribed, 
meaning that the majority of the human transcriptome is comprised of 
noncoding RNAs (ncRNAs), genes that are transcribed into RNA but 
not translated into protein.9 NcRNAs are classified by their size as small 
ncRNAs (<200 bp) or long ncRNAs (>200 bp).10 One particular class 
of small ncRNAs, microRNAs (miRNAs), has been extensively studied 
in the literature. MiRNAs negatively regulate the protein expression 
of a gene via binding to the 3’ untranslated region of the target gene 
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Prostate cancer is the second most common cause of cancer mortality among men in the United States. While many prostate 
cancers are indolent, an important subset of patients experiences disease recurrence after conventional therapy and progresses to 
castration‑resistant prostate cancer (CRPC), which is currently incurable. Thus, there is a critical need to identify biomarkers that will 
distinguish indolent from aggressive disease, as well as novel therapeutic targets for the prevention or treatment of CRPC. In recent 
years, long noncoding RNAs (lncRNAs) have emerged as an important class of biological molecules. LncRNAs are polyadenylated 
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in the progression of prostate cancer and evaluate their use as potential biomarkers and therapeutic targets.
Asian Journal of Andrology (2016) 18, 568–574; doi: 10.4103/1008-682X.177123; published online: 12 April 2016
Keywords: biomarker; long noncoding RNAs (lncRNAs); prostate cancer
1Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA; 2Department of Radiation Oncology, Urology, and Medicine, University of California 
at San Francisco, USA; 3Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, USA.
Correspondence: Dr. FY Feng (Felix.Feng@ucsf.edu)
Open Access
Pr
os
ta
te
 C
an
ce
r
Asian Journal of Andrology 
Prostate cancer‑associated lncRNAs 
B Malik and FY Feng
569
were characterized to be lineage- or cancer-specific, suggesting that 
lncRNAs are very attractive as potential biomarkers or therapeutic 
targets.
POTENTIAL MECHANISMS AND FUNCTIONS OF LNCRNAS
LncRNAs are nonprotein-coding genes characterized by several features. 
While the majority of lncRNAs is polyadenylated and transcribed by 
RNA polymerase II, a significant subset is nonpolyadenylated and 
transcribed by RNA polymerase III. As other transcribed genes, 
lncRNAs harbor epigenetic marks, such as trimethylation of histone 
3 lysine 4 (H3K4me3) at the promoter region and trimethylation of 
histone 3 lysine 36 (H3K36me3) throughout the body of the gene.16 
Moreover, lncRNAs exhibit frequent splicing of multiple exons and are 
expressed in a cell- and tissue-specific manner.9,17,18
Similar to protein-coding genes, lncRNAs vary considerably in 
function. The function of lncRNAs often relates to the transcriptional 
regulation of genes leading to differential mRNA processing. There 
are different ways by which lncRNAs function to regulate target gene 
expression, as shown in Figure 2. The most common mode of gene 
regulation involves an epigenetic mechanism that typically results in 
transcriptional repression by coupling with chromatin-remodeling 
or histone-modifying protein complexes.19 Among all the chromatin 
remodeling complexes, the most common protein partners for 
lncRNAs are Polycomb Repressive Complexes 1 and 2  (PRC1 and 
PRC2). LncRNAs serve as scaffolds that mediate the recruitment of 
these Polycomb Repressive Complexes to certain genomic regions to 
guide transcriptional regulation.
In addition to transcriptional regulation by epigenetic changes, 
lncRNAs are also known to be involved in mRNA processing, 
including mRNA stability, splicing, and translation (Figure 2). These 
posttranscriptional RNA modifications, including alternative splicing, 
involve the assembly of RNA-processing factors containing nuclear 
domains at certain genomic sites.20 Moreover, lncRNAs can function 
as decoys or molecular sponges for miRNAs that target protein-coding 
mRNAs. In this way, lncRNAs sequester miRNAs to regulate gene 
expression indirectly.21 Furthermore, emerging evidence suggests a 
role for certain lncRNAs, termed enhancer RNAs (eRNAs), in gene 
regulation via influencing the activity of gene enhancers. These 
eRNAs are transcribed from gene enhancers, and can cooperate 
with lineage-specific complexes, such as FOXA1 and AR, to facilitate 
hormone signaling pathways.22
Mechanistically, lncRNAs can be characterized as cis-  and 
trans-regulators of gene expression based on whether they target genes 
that are local or distant, respectively, from their genomic location. For 
example, lncRNAs have been shown to regulate gene expression in 
both cis- and trans-based approaches by facilitating the recruitment 
of PRC2 complexes to local and distant genes.23,24 Taken together, it is 
clear that the mechanisms by which lncRNAs regulate gene expression 
are quite complex, with further investigation necessary to more clearly 
decipher the role of lncRNAs.
Through the functions highlighted in Figure  2, lncRNAs 
can function as oncogenes or tumor suppressors by modulating 
physiological and pathological processes, including cell growth and 
differentiation, stem cell reprogramming, and disease progression. 
Many lncRNAs have been shown to be either up- or down-regulated 
in various cancers, including prostate cancer, and are associated 
with disease progression. In fact, using high-throughput approaches 
to interrogate RNA expression in over a thousand prostate cancer 
patients treated with prostatectomy, a recent study from our group 
demonstrated that among all protein-coding genes and lncRNAs 
annotated at the time of the study, the lncRNA SChLAP1 was the top 
overexpressed gene in cancers that subsequently metastasized versus 
those that did not.25 The finding that the prognostic value of lncRNAs 
may rival or outperform that of top protein-coding genes has significant 
implications for clinical biomarker development in prostate cancer. 
Below, we highlight several lncRNAs that have been implicated in 
prostate carcinogenesis or progression.
PROSTATE CANCER‑ASSOCIATED LNCRNAS
Since the initial discovery of lncRNAs such as XIST and H19, there have 
been dramatic advances in the high-throughput technologies, thereby 
enabling the discovery of RNA transcripts in an unbiased manner.15,26–31 
Since then, many lncRNAs have been linked to tumorigenesis, either 
as oncogenes or tumor suppressors. While the underlying mechanism 
of many of these lncRNAs remains to be elucidated, it is clear that 
lncRNAs contribute to dysregulation of gene expression in prostate 
cancer, which then results in cancer initiation, development, and 
progression.15
One of the first lncRNAs discovered to be highly upregulated 
in prostate cancer  (PCa) was Prostate Cancer Antigen 3  (PCA3), 
which was initially discovered via expression profiling of PCa 
samples.32 PCA3 was shown to be significantly overexpressed in 
PCa versus adjacent noncancerous prostate tissues in 95% of radical 
prostatectomy specimens.32 Extensive analysis of the genomic loci of 
PCA3  (Chr9q21–22) demonstrated no open reading frame for this 
gene, consistent with a noncoding RNA transcript.32 A preclinical 
study suggested that knockdown of PCA3 hinders PCa cell viability 
and alters the expression of AR target genes.33 More recently, it 
was reported that PCA3 is antisense to the tumor-suppressive 
protein-coding gene PRUNE2 and downregulates the expression of 
PRUNE2 via RNA editing mediated by a supramolecular complex 
containing adenosine deaminase acting on RNA  (ADAR) family 
members.34 Following the discovery of PCA3, other lncRNAs including 
Prostate Cancer-associated ncRNA Transcript 1 (PCAT1) and Second 
Chromosome Locus Associated with Prostate-1 (SChLAP1) were found 
to be differentially expressed in prostate cancer versus nonneoplastic 
prostate tissues.15,35
PCAT1 was discovered as a prostate cancer-associated intergenic 
ncRNA in a cohort of 102 prostate tissues and cell lines via 
high-throughput RNAseq studies.15 PCAT1 is highly prostate-specific 
and is remarkably upregulated in a subset of localized and metastatic 
prostate cancer tissues compared to adjacent nonneoplastic prostate 
tissues.15 The mechanisms by which PCAT1 contributes to prostate 
Figure 1: Classification of long noncoding RNAs. Long noncoding 
RNAs (lncRNAs) are categorized as exonic, intronic, intergenic, antisense, 
or overlapping based on their genomic location relative to a protein‑coding 
gene. Exonic lncRNAs share exons with a protein‑coding gene. Intronic 
lncRNAs are transcribed within the introns of a protein‑coding gene. Intergenic 
lncRNAs are transcribed within the regions between two protein‑coding genes. 
Antisense lncRNAs are located on the opposite strand from a protein‑coding 
gene. Overlapping lncRNAs are transcripts that contain a protein‑coding 
gene within its intron.
Asian Journal of Andrology 
Prostate cancer‑associated lncRNAs 
B Malik and FY Feng
570
carcinogenesis and progression have been studied in a series of 
preclinical studies.36,37 First, PCAT1 represses BRCA2, a DNA repair 
gene critical to homologous recombination, by regulating its 3’ 
untranslated region  (UTR). This repression leads to a functional 
deficiency in homologous recombination, resulting in sensitivity to 
PARP1 inhibitors and radiation.36  Second, PCAT1 also promotes 
prostate cell proliferation through the upregulation of c-Myc.37 
Collectively, these data suggest that PCAT1 contributes to disease 
progression via two complementary approaches: one where PCAT1 
represses BRCA2 to create deficiencies in DNA damage repair to 
promote carcinogenesis and another where PCAT1 facilitates prostate 
cell proliferation via regulating c-Myc. Given that DNA repair defects 
and unchecked proliferation represent two of the hallmarks of cancer, 
PCAT1 may represent a prostate cancer biomarker that may hold 
value as both a biomarker prognostic of outcome but also predictive 
of response to particular therapies.
SChLAP1 was discovered as a highly expressed intergenic lncRNA 
associated with aggressive disease in subset of prostate cancer patients 
via cancer outlier profile analysis  (COPA).35 As described earlier, 
SChLAP1 is notable for being one of the genes most enriched in 
expression in prostate cancers that will metastasize compared to 
those that do not.25 SChLAP1 expression has been shown to be an 
independent predictor of aggressive prostate cancer when accounting 
for standard clinicopathological factors, with high SChLAP1 expression 
associated with biochemical recurrence, metastatic progression, 
and prostate cancer-specific mortality.25 SChLAP1 also significantly 
promotes cancer cell proliferation, invasion, and metastasis in vitro 
and in vivo. Mechanistically, SChLAP1 facilitates aggressive phenotypes 
associated with cancer by antagonizing the tumor suppressive SWI/SNF 
(Switch/Sucrose Nonfermenting) chromatin remodeling complex. 
The multiprotein SWI/SNF complex regulates gene transcription by 
physically moving nucleosomes at the gene promoters.38 SChLAP1 
has been shown to interact with SNF5, a key component of 
SWI/SNF complex, and impairs the genomic binding of SNF5, thereby 
antagonizing the tumor suppressive function of SWI/SNF complex.35 
SChLAP1 is currently developed as a prognostic biomarker using an 
RNA in situ hybridization assay.39,40
Recent studies have also identified that lncRNAs may interact with 
the androgen receptor (AR), a well-known driver of prostate cancer. 
Two lncRNAs, PCGEM1 and PRNCR1, have been proposed to be 
highly upregulated in primary prostate cancer versus normal prostate 
epithelium.41,42 In laboratory studies, increased cell proliferation and 
colony formation were observed with overexpression of PCGEM1, 
along with attenuated apoptotic response.43 In addition, the knockdown 
of PRNCR1 resulted in decreased cell viability.44 These lncRNAs have 
been reported to bind AR and enhance AR-mediated gene activation 
programs.41,42 However, this area requires further study as the second 
study could not confirm the role of PCGEM1 and PRNCR1 in prostate 
cancer progression and AR signaling.45 In addition, another recent 
publication demonstrated the upregulation of PCGEM1 but not 
PRNCR1 in AR+/androgen-dependent PCa xenograft models.46 In 
addition to its potential AR-associated roles, PCGEM1 may regulate 
tumor metabolism via c-Myc activation, by interacting physically with 
c-Myc and enhancing its chromatin recruitment and transactivation 
activity.47
Several other lncRNAs have also been implicated as mediators 
or modulators of AR signaling. One study suggested that reciprocal 
regulation between the lncRNA PlncRNA‑1 and AR contributes 
Figure 2: Functions of long noncoding RNAs. Long noncoding RNAs (lncRNAs) regulate target gene expression in a variety of approaches, including the 
following: (1) LncRNAs can interact with transcriptional activators, thereby leading to target gene activation. (2) LncRNAs may mediate transcriptional 
repression either by directly affecting tumor suppressor signaling or by acting as decoy to keep transcriptional activators away from chromatin. (3) LncRNAs 
transcribed from gene enhancers (eRNAs) may regulate signaling by recruiting lineage‑specific complexes. (4) LncRNAs may serve as scaffolding proteins by 
recruiting chromatin remodeling complexes, including PRC1 and PRC2. (5) LncRNAs may regulate RNA splicing either by interacting with splicing factors 
or by binding the splicing junctions of pre‑mRNA. (6) LncRNAs may serve as molecular sponges by harboring binding sites for miRNAs and titrating them 
away from their mRNA targets. eRNA: enhancer RNA, GTF: general transcription factors, LncRNA: long noncoding RNA, mRNA: messenger RNA, miRNA: 
microRNA, Pol II: RNA polymerase II, PRC2: polycomb repressive complex 2, TF: transcription factors, UTR: untranslated region.
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to oncogenic phenotypes in  vitro.48 Another androgen responsive 
lncRNA, C-terminal binding protein 1-antisense  (CTBP1‑AS), 
was demonstrated to promote both androgen-dependent and 
castration-resistant tumor growth by directly repressing the expression 
of its antisense gene CTBP1, a known AR corepressor.49 More recently, 
a novel lncRNA cluster DRAIC/PCAT29 has been shown to inhibit 
cancer cell migration and invasion.50,51 Mechanistically, the expression 
of DRAIC is repressed by binding of AR to the DRAIC locus but is 
induced by binding of FOXA1 and NKX3-1 to the same locus as AR. 
Together, these studies suggest that as the expressions of FOXA1 and 
NKX3-1 decrease with prostate cancer progression, there is decreased 
expression of the tumor suppressive DRAIC/PCAT29 lncRNAs, leading 
to aggressive phenotypes.50,51
Outside of AR, lncRNAs have been demonstrated to be involved 
in mediating the function of other potential prostate cancer drivers. 
The estrogen receptor alpha  (ERα) is expressed in subsets of PCa, 
independent of AR status, and may be associated with aggressive 
disease. Chakravarty et  al. developed an ERα-specific noncoding 
transcriptome signature, and used this signature to identify Nuclear 
Enriched Abundant Transcript 1 (NEAT1) as the most significantly 
overexpressed ERα-regulated lncRNA in PCa.52 This group also 
demonstrated that PCa cells with high expression of NEAT1 
are resistant to androgen receptor antagonists.52 Another group 
identified 145 previously unannotated lncRNAs associated with 
castration-resistant prostate cancer (CRPC) and characterized one of 
these, PCAT5, as a regulatory target of the transcription factor ERG, 
which is activated in 50% of all prostate cancers.53 Furthermore, by 
profiling androgen-dependent versus androgen-independent cell 
lines, another team recently identified Linc00963 as a lncRNA which 
regulates the epidermal growth factor receptor signaling pathway to 
promote cell growth, migration, and invasion.54
Another intriguing lncRNA in prostate cancer biology is Antisense 
Noncoding RNA in the INK4 Locus (ANRIL), which has been shown 
to have an important role in cancer biology and is one of the best 
studied natural antisense transcript genes. It is an antisense transcript 
overlapping the tumor suppressor INK4b‑ARF‑INK4a gene cluster 
and is one of the most frequently altered lncRNAs in cancer.55 There is 
either homozygous deletion or transcriptional silencing of the ANRIL 
gene cluster in almost 40% of human cancers.56 The INK4b‑ARF‑INK4a 
gene cluster plays an important role in stress-induced apoptosis, cell 
cycle inhibition, and senescence, and the expression of this gene cluster 
has been shown to be repressed by the expression of ANRIL.55,57,58 The 
expression of ANRIL is higher in preneoplastic prostate epithelial 
tissues compared to untransformed prostate epithelial tissues. In 
addition, there are higher levels of ANRIL in prostate cancer relative 
to normal prostate epithelial cells with a corresponding decrease 
in the expression of INK4a.59 In coordination with the PRC1 and 
PRC2 complexes, ANRIL leads to the transcriptional silencing of 
INK4b‑ARF‑INK4a locus via directly binding to INK4b transcripts. 
Moreover, in ANRIL knockdown studies, reduced levels of histone 
H3 lysine K27 methylation  (H3K27me) has been reported at the 
INK4b‑ARF‑INK4a locus.59 In addition, the role of ANRIL has also 
been studied in DNA damage response. Upon DNA damage, the 
expression of ANRIL is induced by E2F1 transcription factor in an 
ATM-dependent manner.60 Further, the elevated ANRIL expression 
suppresses the expression of INK4b‑ARF‑INK4a locus. Thus, ANRIL 
could represent an interesting therapeutic target to sensitize cancers 
to DNA damaging drugs.
In prostate cancer, the lncRNA Metastasis-associated Lung 
Adenocarcinoma Transcript 1 (MALAT1) is involved in mRNA splicing 
and is highly upregulated. MALAT1 is an intergenic lncRNA on 
chromosome locus 11q13.1 that is thought to regulate gene expression 
through mRNA splicing and editing.61 MALAT1 is primarily located 
in nuclear speckles and overexpressed in a variety of human cancers, 
including prostate cancer, and has been linked to poor prognosis.61–64 
Moreover, knockdown of MALAT1 in prostate cancer cell lines 
abrogates cell growth, migration and invasion, and induced G0/G1 cell 
cycle arrest. Therapeutically, MALAT1 has been targeted in prostate 
cancer xenografts with intratumoral delivery of MALAT1 siRNA, 
resulting in significant reduction in tumor growth and metastasis.65
In contrast to the many oncogenic lncRNAs, fewer have been 
reported as tumor suppressor lncRNAs in prostate cancer. Growth 
Arrest-Specific Transcript 5  (GAS5) is a lncRNA that is highly 
upregulated in normal prostate epithelial cells but decreases in 
expression in prostate cancer cell lines. GAS5 manifests multiple 
isoforms that constitute approximately 12 exons. Mechanistically, GAS5 
promotes cell apoptosis by antagonizing glucocorticoid receptor (GR) 
signaling axis in breast cancer. Similarly in prostate cancer, GAS5 is 
suspected to regulate androgen receptor-mediated signaling to prevent 
the progression to metastatic castration-resistant disease.66 Another 
lncRNA, Maternally Expressed Gene 3  (MEG3) has been shown to 
be downregulated in prostate cancer cell lines and primary tumors 
compared to normal tissues. MEG3 is proposed to induce apoptosis 
in both p53 dependent and independent manners.67,68
Our understanding of the potential roles of long noncoding RNAs 
in prostate cancer is starting to develop. However, given the discovery 
of >40 000 novel lncRNAs on recent transcriptome sequencing studies, 
it is also clear that much additional research needs to be performed in 
this area, to understand the molecular mechanisms underlying these 
genes. In addition, given that many of these lncRNAs are highly tissue- or 
lineage-specific, there is a clear need to pursue top candidates as potential 
biomarkers and therapeutic targets. In the following section, we discuss 
the potential clinical significance of lncRNAs in prostate cancer.
OPPORTUNITIES TO UTILIZE LNCRNAS IN THE CLINICAL 
MANAGEMENT OF PROSTATE CANCER
In the clinical management of prostate cancer, there is a critical need 
to better tailor therapy based on individual tumor characteristics. To 
improve the personalization of therapy for patients, two goals need 
to be achieved:  (1) the identification of biomarkers to distinguish 
indolent from aggressive disease, in the context of diagnosis or 
work-up of localized disease and (2) the discovery of novel prostate 
cancer drivers, which can serve as new therapeutic targets in subsets 
of patients. Therefore, lncRNAs have the potential to contribute toward 
both of these goals.
As potential prostate cancer diagnostic and prognostic biomarkers, 
lncRNAs exhibit several ideal qualities. First, certain lncRNAs are 
expressed at extremely high levels in subsets of cancers and exhibit 
outlier profiles,14 which facilitates their detection in both tissue and 
bodily fluids. Second, significant subsets of lncRNAs are extremely 
specific for a particular cancer, considering that a recent study 
discovered approximately 8000 novel lncRNAs which are extremely 
cancer- or lineage-specific.14,25 A number of these lncRNAs are specific 
for prostate cancer,25 and this specificity is an ideal trait for a potential 
noninvasive biomarker. Finally, lncRNAs represent a vastly unexplored 
area of cancer biology, and given that they outnumber protein-coding 
genes,14 there are likely many clinically relevant lncRNA biomarkers 
that are, to date, uncharacterized.
Up to now, the best-studied lncRNA biomarker is PCA3, which 
has been explored extensively as a urinary biomarker. Following the 
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initial discovery and characterization of PCA3 as a highly overexpressed 
lncRNA specific to prostate cancer,32 a clinical assay was developed 
and introduced for the detection of urinary PCA3 levels. This assay, 
named the Progensa PCA3 assay,69 required urine specimens to be 
obtained after digital rectal examination (3 strokes to each lobe), and 
quantified PCA3 transcript expression based on transcription-mediated 
amplification and hybridization, and normalized PCA3 levels based 
on prostate-specific antigen  (PSA) transcript levels. Early studies 
demonstrated that the PCA3 test improved the ability to diagnose 
prostate cancer, with a univariable AUC of 0.69 (compared to an AUC 
of 0.55 for PSA) that increased to 0.75 in a multivariable model with 
other clinical factors.70 PCA3 was demonstrated to be independent 
of PSA levels, prostate volume, or age.71 Based on these findings and 
others, the Food and Drug Administration approved the PCA3 assay 
for use as a diagnostic test in men with a previous negative biopsy.72,73 
Subsequent studies have focused on identifying the optimal cut-off 
score of PCA3 in the context of clinical use. A meta-analysis from Luo 
et al. evaluated the performance of threshold scores ranging from 20 to 
35 and concluded that a cut-off of 20 was superior to 35 in the repeat 
biopsy setting, with a sensitivity of 93% and a specificity of 64%.74 In 
the context of the National Cancer Institute Early Detection Research 
Network validation trial, Wei et al. confirmed that PCA3 scores <20 
were associated with an extremely low rate of high-grade cancers on 
repeat biopsy.75 In more recent years, studies have investigated the 
PCA3 test in the setting of initial  (rather than repeat) biopsy and 
have compared the PCA3 to other assays. Overall, these studies have 
suggested that in limited cohorts, PCA3 may not perform as well 
compared to other diagnostic tests, such as multi-parametric MRI or 
the Prostate Health Index test.76 These results indicate that while PCA3 
may outperform PSA, further studies need to be performed to define 
the optimal clinical settings for its use.
While the PCA3 assay is designed to diagnose prostate cancer, 
its utility as a prognostic biomarker is much more limited as it can 
detect both higher-grade and lower-grade disease.75 A more promising 
prognostic urine biomarker is SChLAP1, which has been readily 
detected in urine sediments through qPCR.25 Since SChLAP1 was 
identified as the top overexpressed gene enriched in prostate cancer 
tissue samples  (n  >  1000) from high-risk patients who eventually 
experienced metastatic progression versus those who did not,25 
SChLAP1 may better predict for lethal disease than other candidate 
genes. Preliminary studies suggest that urinary SChLAP1 expression 
also exhibits outlier profiles and predicts for more aggressive disease.25 
In addition to its potential as a urine biomarker, tissue-based assays 
for SChLAP1 are also being developed with SChLAP1 expression 
currently available on the clinically used Decipher array,25 and there 
are also ongoing efforts to validate an RNA in situ hybridization assay 
for SChLAP1 as well.40,77
In addition to serving as potential prognostic biomarkers 
(i.e.,  biomarkers associated with poor outcomes independent 
of treatment), lncRNAs may also serve as biomarkers which 
specifically predict response or resistance to particular therapies. The 
ERα-regulated lncRNA NEAT1 has been reported to confer resistance 
to anti-androgen therapies in laboratory models,52 additional studies 
are necessary to determine if this finding validates in clinical samples. 
More recently, PARP1 inhibition has been identified as a promising 
therapeutic approach in patients with castration-resistant prostate 
cancers harboring alterations in DNA repair genes.78 Given preclinical 
findings that the lncRNA PCAT1 confers defects in homologous 
recombination in vitro and sensitivity to PARP1 inhibitors in vivo,36 
PCAT1 represents a promising biomarker of response to PARP1 
inhibition although this finding needs to be further assessed in clinical 
samples as well.
Ultimately, the “holy grail” in utilizing lncRNAs to personalize 
therapy will entail the development of successful strategies to target 
lncRNAs clinically. Currently, RNA interference approaches, with small 
interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), miRNAs, 
and antisense oligonucleotides (ASOs), represent a promising strategy 
for targeting lncRNAs. Within in vivo models, targeting SChLAP1 with 
shRNA-based approaches decreases metastases in a tail-vein injection 
model.35 In addition, intratumoral delivery of therapeutic siRNAs 
directed against MALAT‑1 delays xenograft growth in castrated mice.65 
ASOs have been developed against MALAT‑1 and demonstrated to be 
effective in lung cancer xenograft models, supporting the investigation 
of ASOs in prostate cancer models as well. While RNA interference 
strategies have shown promise in preclinical models of prostate and 
other cancers, there are several challenges that must be overcome 
in the clinical application of these approaches. These issues include 
optimizing delivery systems for appropriate dosing/distribution and 
ensuring stability of RNA targeting agents among other issues. To date, 
a number of siRNA- and ASO-based agents are assessed in both early 
and late clinical trials for various disease and cancer indications.79,80 
Further research is necessary to determine if these RNA-targeting 
strategies can be successfully applied to prostate cancer lncRNAs.
SUMMARY
Recent advances in RNAseq technologies, combined with large-scale 
efforts to sequence patient samples, have drastically enhanced the 
discovery of disease-associated lncRNAs.14 While several prostate 
cancer lncRNAs promote aggressive phenotypes in preclinical models 
and are associated with disease progression in clinical cohorts, the 
underlying mechanisms of these oncogenic lncRNAs need to be 
further investigated. It is clear that lncRNAs are very promising as 
diagnostic, prognostic, and predictive biomarkers in prostate cancer. 
Only time will tell if prostate cancer lncRNAs can be successfully 
targeted therapeutically, but this area of research holds tremendous 
potential.
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